R Squared’s VistaGen Therapeutics VTGN Stock Holding History

R Squared’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-8,610	Closed	-$25.4K	–	1503
2024 Q4	$25.4K	Buy	+8,610	New	+$24.2K	0.02%	775

Other funds holding VTGN

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

JP Morgan Chase

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

R Squared's VTGN Position: Q1 2025 in Review

R Squared sold out of VistaGen Therapeutics (VTGN) in Q1 2025, closing a stake of 8,610 shares — an estimated $25.4K sold.

R Squared first reported a position in VTGN in Q4 2024 and held it in 1 quarter. The position peaked at $25.4K in Q4 2024. 48 funds tracked by Wall St. Rank hold VTGN as of Q1 2025.

R Squared reported no remaining VistaGen Therapeutics position as of Q1 2025 after selling out during the quarter.
R Squared sold 8,610 VistaGen Therapeutics shares in Q1 2025, an estimated $25.4K.
R Squared first reported a position in VistaGen Therapeutics in Q4 2024 and held it in 1 quarter.
R Squared's VistaGen Therapeutics position peaked at $25.4K in Q4 2024.
48 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.